Brookfield Asst Financials
Financial Health Signals
Brookfield Asst passes 3 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Brookfield Asst generates $1.16 in operating cash flow ($627.0M OCF vs $541.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
This page shows Brookfield Asst (BAM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Brookfield Asst reported $541.0M in net income in fiscal year 2024. This represents an increase of 20.0% from the prior year.
Brookfield Asst held $404.0M in cash against $0 in long-term debt as of fiscal year 2024.
Brookfield Asst paid $1.52 per share in dividends in fiscal year 2024. This represents an increase of 18.8% from the prior year.
Brookfield Asst's ROE was 6.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 15.5 percentage points from the prior year.
BAM Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B+14.9% | $1.1B+0.8% | $1.1B-3.2% | $1.1B+21.9% | $916.0M+3.6% | $884.0M | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $23.0M+27.8% | $18.0M+200.0% | $6.0M-70.0% | $20.0M+53.8% | $13.0M+44.4% | $9.0M | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $20.0M-35.5% | $31.0M+933.3% | $3.0M-62.5% | $8.0M+166.7% | $3.0M-25.0% | $4.0M | N/A | $2.0M |
| Income Tax | $78.0M+4.0% | $75.0M0.0% | $75.0M-21.9% | $96.0M-32.4% | $142.0M+100.0% | $71.0M | N/A | N/A |
| Net Income | $692.0M+18.5% | $584.0M+15.2% | $507.0M-5.6% | $537.0M+3.7% | $518.0M+38.9% | $373.0M | N/A | $109.0M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0.28 |
BAM Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $16.5B+2.3% | $16.1B+7.9% | $15.0B+5.7% | $14.2B+238.3% | $4.2B | N/A | $3.2B+1.2% | $3.2B |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $1.1B+121.2% | $480.0M+44.6% | $332.0M-17.8% | $404.0M+3940.0% | $10.0M-99.6% | $2.6B+28722.2% | $9.0M-25.0% | $12.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.8B+14.4% | $5.1B+25.5% | $4.1B+37.3% | $3.0B+220.6% | $925.0M | N/A | $1.1B+19.9% | $934.0M |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $8.5B-0.1% | $8.5B-0.2% | $8.5B-3.0% | $8.8B+171.0% | $3.2B-64.2% | $9.0B+334.2% | $2.1B-7.1% | $2.2B |
| Retained Earnings | -$704.0M+1.5% | -$715.0M-15.9% | -$617.0M-26.4% | -$488.0M-310.1% | -$119.0M | N/A | -$35.0M-3400.0% | -$1.0M |
BAM Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $745.0M+40.8% | $529.0M+99.6% | $265.0M+131.2% | -$849.0M-316.0% | $393.0M-23.8% | $516.0M | N/A | $134.0M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$8.0M+98.4% | -$490.0M-683.3% | $84.0M-95.2% | $1.7B+485.0% | -$452.0M-7433.3% | -$6.0M | N/A | $0 |
| Financing Cash Flow | -$161.0M-249.1% | $108.0M+125.6% | -$422.0M-148.1% | $877.0M+245.4% | -$603.0M-4.0% | -$580.0M | N/A | -$134.0M |
| Dividends Paid | $706.0M+0.6% | $702.0M-0.7% | $707.0M+157.5% | -$1.2B-298.5% | $619.0M-0.2% | $620.0M | N/A | $127.0M |
| Share Buybacks | $69.0M | $0-100.0% | $116.0M | $0 | $0 | $0 | N/A | $35.0M |
BAM Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 55.3%+1.7pp | 53.6%+6.7pp | 46.9%-1.2pp | 48.1%-8.5pp | 56.5%+14.4pp | 42.2% | N/A | N/A |
| Return on Equity | 8.2%+1.3pp | 6.9%+0.9pp | 6.0%0.0pp | 6.0%-10.1pp | 16.0%+11.9pp | 4.1% | N/A | 4.9% |
| Return on Assets | 4.2%+0.6pp | 3.6%+0.2pp | 3.4% | N/A | 12.4% | N/A | N/A | 3.4% |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.69+0.1 | 0.60+0.1 | 0.48+0.1 | 0.34+0.1 | 0.29 | N/A | 0.54+0.1 | 0.42 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Brookfield Asst profitable?
Yes, Brookfield Asst (BAM) reported a net income of $541.0M in fiscal year 2024.
Does Brookfield Asst pay dividends?
Yes, Brookfield Asst (BAM) paid $1.52 per share in dividends during fiscal year 2024.
What is Brookfield Asst's return on equity (ROE)?
Brookfield Asst (BAM) has a return on equity of 6.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Brookfield Asst's operating cash flow?
Brookfield Asst (BAM) generated $627.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Brookfield Asst's total assets?
Brookfield Asst (BAM) had $14.2B in total assets as of fiscal year 2024, including both current and long-term assets.
What is Brookfield Asst's debt-to-equity ratio?
Brookfield Asst (BAM) had a debt-to-equity ratio of 0.34 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Brookfield Asst's return on assets (ROA)?
Brookfield Asst (BAM) had a return on assets of 3.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Brookfield Asst's Piotroski F-Score?
Brookfield Asst (BAM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Brookfield Asst's earnings high quality?
Brookfield Asst (BAM) has an earnings quality ratio of 1.16x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.